ACEI trials in CAD without HF: Primary outcomes

1
ACEI trials in CAD without HF Primary outcomes
VBWG
EUROPA CV death/MI/cardiac arrest
HOPECV death/MI/stroke
14
20
Placebo
12
Placebo
15
10
22 Risk reduction HR 0.78 (0.700.86) P lt 0.001
20 Risk reduction HR 0.80 (0.710.91) P 0.0003
Ramipril 10 mg
8


10
6
Perindopril 8 mg
4
5
2
0
0
1
3
4
0
5
2
0
2
4
1
3
Time (years)
Time (years)
PEACECV death/MI/CABG/PCI
QUIETAll CV events
Placebo
50
30
Quinapril 20 mg
40
25
4 Risk increase HR 1.04 (0.891.22) P 0.6
20
4 Risk reduction HR 0.96 (0.881.06) P 0.43
30
Trandolapril 4 mg


Placebo
15
20
10
10
5
0
0
1
2
3
4
5
6
0
1
2
3
Time (years)
Time (years)
HOPE Study Investigators. N Engl J Med.
2000342145-53. Pitt B et al. Am J Cardiol.
2001871058-63.
EUROPA Investigators. Lancet. 2003362782-8. PEAC
E Trial Investigators. N Engl J Med.
20043512058-68.